# TME Pharma Grants TMS Six Months of Exclusivity for NOX-A12 in €150,000 Deal

> TME Pharma receives €150,000 for six months of exclusive NOX-A12 talks with Japan's TMS, with €10 million in short-term payments and over €100 million in milestones.

- Published: 2026-10-29T07:25:58+00:00
- Section: Partnerships
- Author: News Desk
- URL: https://newsforagent.com/news/2026-10-29/tme-pharma-tms-nox-a12-exclusivity
- Source: [GlobeNewswire](https://www.globenewswire.com/news-release/2026/10/29/3390960/0/fr/tme-pharma-signe-un-accord-de-n%C3%A9gociation-exclusif-et-contraignant-avec-la-soci%C3%A9t%C3%A9-japonaise-tms-co-ltd.html)

## Key takeaways

- TME Pharma will receive a non-refundable €150,000 fee from TMS Co., Ltd. for a six-month exclusive negotiation period on NOX-A12.
- Non-binding terms include about €10 million in short-term payments and more than €100 million in regulatory and commercial milestones.
- TMS will create a subsidiary to fund and resume the GLORIA Phase 2 study of NOX-A12 in glioblastoma.

TME Pharma has signed a binding exclusive negotiation agreement with Japanese clinical-stage biotech TMS Co., Ltd. covering worldwide rights to its glioblastoma drug NOX-A12, receiving €150,000 for six months of exclusivity. The Berlin company announced the agreement on October 29, 2026, according to [GlobeNewswire](https://www.globenewswire.com/news-release/2026/10/29/3390960/0/fr/tme-pharma-signe-un-accord-de-n%C3%A9gociation-exclusif-et-contraignant-avec-la-soci%C3%A9t%C3%A9-japonaise-tms-co-ltd.html).

## How the TMS Exclusivity Agreement Works

Under the binding agreement, [TME Pharma](https://akta.pro/company-profiles/0002hzu/tme-pharma) will not solicit or accept offers from third parties, or hold licensing, development or commercialization discussions with anyone other than TMS and its subsidiary, during the six-month period. The exclusivity can be extended with additional payments.

The two companies also signed a non-binding letter of intent setting out terms that remain subject to renegotiation. At signing of a definitive agreement, TME Pharma would receive about €10 million in short-term payments, a combination of cash and an equity and debt stake in the TMS subsidiary. The terms include more than €100 million in regulatory and commercial sales-linked milestones, royalties of 8% to 10% on sales that TME Pharma projects to peak at about $1 billion, and a share of sublicense royalties collected by the subsidiary.

TMS will form the subsidiary to lead the financing process, and TME Pharma will continue developing NOX-A12 as a partner and minority shareholder. The companies set a roadmap to finalize the definitive agreement, which they describe as a key step toward resuming the Phase 2 GLORIA study of NOX-A12.

"En choisissant TMS Co. Ltd., nous pensons avoir trouvé un excellent partenaire pour exploiter pleinement le potentiel du NOX-A12 et relancer la création de valeur en reprenant le développement clinique pour le glioblastome," said Diede van den Ouden, CEO.

## NOX-A12 Data Behind the Deal

According to akta.pro [company records](https://akta.pro/company-data), results from the GLORIA Phase 1/2 expansion Arm A were published in Nature Communications in April 2026, reporting median overall survival of 19.9 months versus 9.5 months for standard of care, with p=0.003, for NOX-A12 plus radiotherapy and bevacizumab in newly diagnosed MGMT-unmethylated glioblastoma. The same records list 17 funding rounds, including a $2.6 million grant in October 2024 led by the German Federal Ministry of Research, Technology and Space.

## TME Pharma's Partner Search Before TMS

On August 24, 2026, TME Pharma said it had narrowed its search for a partner for NOX-A12 to two suitors in the final evaluation phase of advanced discussions, FierceBiotech reported. A separate August 24, 2026 update said the company had entered the final evaluation phase of discussions with two potential partners to license NOX-A12 for glioblastoma treatment, FinanzNachrichten.de reported.

## What Comes Next for the GLORIA Study

The companies agreed on a roadmap to finalize the definitive agreement, which they state is a key step toward restarting the Phase 2 GLORIA study of NOX-A12. TME Pharma said the subsidiary will lead the financing process for that development.

## Companies in this story

- [TME Pharma company profile](https://akta.pro/company-profiles/0002hzu/tme-pharma) · website: https://www.tmepharma.com

---
News for Agent · https://newsforagent.com/llms.txt